FLY INVESTOR NOTICE: Firefly Aerospace Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Firefly Aerospace Inc. (NASDAQ: FLY): (i) securities between August 7, 2025 and September 29, 2025, inclusive (the “Class Period”); and/or (ii) common stock pursuant and/or traceable to Firefly Aerospace's offering documents issued in connection with Firefly Aerospace's August 7, […]

PRGO Investors Have Opportunity to Lead Perrigo Company plc Securities Fraud Lawsuit

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Perrigo Company plc (NYSE: PRGO) between February 27, 2023 and November 4, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline. So what: If you purchased Perrigo securitiesduring the Class Period you

JYD Investors Have Opportunity to Lead Jayud Global Logistics Ltd. Securities Fraud Lawsuit

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jayud Global Logistics Ltd. (NASDAQ: JYD) between April 21, 2023 and April 30, 2025, both dates inclusive (the “Class Period”), of the important January 20, 2026 lead plaintiff deadline. So what: If you purchased Jayud securitiesduring the Class Period

INSP Investors Have Opportunity to Lead Inspire Medical Systems, Inc. Securities Fraud Lawsuit

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”), of the important January 5, 2026 lead plaintiff deadline. So what: If you purchased Inspire Medical common stockduring

SFM Investors Have Opportunity to Lead Sprouts Farmers Market, Inc. Securities Fraud Lawsuit

Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of securities and sellers of put options of Sprouts Farmers Market, Inc. (NASDAQ: SFM) between June 4, 2025 and October 29, 2025, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline. So what: If you purchased Skye securitiesduring the Class Period you

Plurilock Announces Appointment of New CFO

Vancouver, British Columbia–(Newsfile Corp. – December 5, 2025) – Plurilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) (“Plurilock” or the “Company”), a global cybersecurity systems integrator, announces the promotion of Veera Singh to Chief Financial Officer, effective January 9, 2026. Mrs. Singh, who currently serves as Vice President of Finance, has been a key contributor to

PRMB, PRMW Investors Have Opportunity to Lead Primo Brands Corporation Securities Fraud Lawsuit

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Primo Water Corporation (NYSE: PRMW) between June 17, 2024 and November 8, 2024, both dates inclusive, and/or (ii) purchasers of common stock of Primo Brands Corporation (NYSE: PRMB) between November 11, 2024 and November 6, 2025 (the “Class

ORIC(R) Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

(NASDAQ:ORIC), Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L patients

Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK

(NASDAQ:ANIK), NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) — The law firm of Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN

Scroll to Top